


Data Sheet

WWW.PROBECHEM.COM

Global Supplier of Chemical Probes, Inhibitors & Agonists.

Molecular Weight: 465.518
Target: Notch

Solubility : 10 mM in DMSO



Biological Activity

NADI-351 is a specific small-molecule inhibitor of **Notch1** transcriptional complexes with IC50 of 8.8 uM in cellualr reporter assays.

NADI-351 inhibited OE33 cell growth in single dose MTT assays (EC50= 10 uM) and, more potently, in multi-dose colony formation assays (EC50=1.3 uM)

NADI-351 is 15 times more potent than IMR-1 in an NTC AlphaScreen assay.

NADI-351 selectively disrupted Notch1 transcription complexes, inhibited recruitment of Notch1 to the NTC (Notch Ternary Complex) and to the HES1 promoter, and reduced Notch1 recruitment to target genes.

NADI-351 inhibits tumor growth in Notch-dependent cancers and does not exert gastrointestinal toxicity associated with goblet cell metaplasia.

NADI-351 selectively inhibits stem-like esophageal adenocarcinoma (EAC) cell populations.

References

Annamil Alvarez-Trotta, et al. *Cancer Res*. 2021 Jun 15;81(12):3347-3357.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com